Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ.

Lancet Oncol. 2012 Jan;13(1):e32-42. doi: 10.1016/S1470-2045(11)70155-3. Review.

PMID:
22225723
2.

Regulatory T cells in the immunotherapy of melanoma.

Ouyang Z, Wu H, Li L, Luo Y, Li X, Huang G.

Tumour Biol. 2016 Jan;37(1):77-85. doi: 10.1007/s13277-015-4315-0. Epub 2015 Oct 30. Review.

PMID:
26515336
3.

Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.

Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T.

Cancer Res. 2010 Oct 15;70(20):7788-99. doi: 10.1158/0008-5472.CAN-10-1736. Epub 2010 Oct 5.

4.

Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.

Knol AC, Lemaître F, Pandolfino MC, Volteau C, Quéreux G, Saiagh S, Khammari A, Viguier M, Dréno B.

Exp Dermatol. 2008 May;17(5):436-45. doi: 10.1111/j.1600-0625.2007.00681.x. Epub 2008 Feb 27.

PMID:
18312383
5.

Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.

Kimpfler S, Sevko A, Ring S, Falk C, Osen W, Frank K, Kato M, Mahnke K, Schadendorf D, Umansky V.

J Immunol. 2009 Nov 15;183(10):6330-7. doi: 10.4049/jimmunol.0900609. Epub 2009 Oct 19.

6.

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.

Tjin EP, Konijnenberg D, Krebbers G, Mallo H, Drijfhout JW, Franken KL, van der Horst CM, Bos JD, Nieweg OE, Kroon BB, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM.

Clin Cancer Res. 2011 Sep 1;17(17):5736-47. doi: 10.1158/1078-0432.CCR-11-0230. Epub 2011 Jul 12.

7.

Regulatory T cells and skin tumors.

Shindo M, Yoshida Y.

Recent Pat Inflamm Allergy Drug Discov. 2010 Nov;4(3):249-54. Review.

PMID:
20673223
8.

Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.

Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, Van Rossum MM, Adema GJ, Figdor CG, Punt CJ, De Vries IJ.

Cancer Res. 2012 Dec 1;72(23):6102-10. doi: 10.1158/0008-5472.CAN-12-2479. Epub 2012 Sep 24.

9.

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.

Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A.

J Natl Cancer Inst. 2015 Dec 30;108(6):djv406. doi: 10.1093/jnci/djv406. Print 2016 Jun.

10.

Next generation of immunotherapy for melanoma.

Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ.

J Clin Oncol. 2008 Jul 10;26(20):3445-55. doi: 10.1200/JCO.2007.14.6423. Review.

PMID:
18612161
11.
12.
13.

Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.

Zhang HH, Mei MH, Fei R, Liao WJ, Wang XY, Qin LL, Wang JH, Wei L, Chen HS.

Int J Oncol. 2010 Apr;36(4):841-8.

PMID:
20198327
14.

[A malignus melanoma immunterápiájának lehetoségei].

Ladányi A.

Magy Onkol. 2003;47(1):113-7. Epub 2003 Apr 18. Review. Hungarian.

15.

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, Karbach J, Jäger E, Sakaguchi S.

Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50. doi: 10.1073/pnas.1316796110. Epub 2013 Oct 14.

16.

Melanoma-induced immunosuppression and its neutralization.

Umansky V, Sevko A.

Semin Cancer Biol. 2012 Aug;22(4):319-26. doi: 10.1016/j.semcancer.2012.02.003. Epub 2012 Feb 13. Review.

PMID:
22349515
17.

Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.

Gajewski TF.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61. Review.

18.

Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.

Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL.

J Immunol. 2008 Mar 1;180(5):2967-80.

19.

Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

Tuve S, Chen BM, Liu Y, Cheng TL, Touré P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR, Lieber A.

Cancer Res. 2007 Jun 15;67(12):5929-39.

20.

Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.

Mazzarella T, Cambiaghi V, Rizzo N, Pilla L, Parolini D, Orsenigo E, Colucci A, Modorati G, Doglioni C, Parmiani G, Maccalli C.

Cancer Immunol Immunother. 2012 Aug;61(8):1169-82. doi: 10.1007/s00262-011-1179-z. Epub 2011 Dec 30.

Supplemental Content

Support Center